Workshop n°1 - Part I
Tuesday, 22 September 2026
11h10
Best Practices in Host Cell Impurity Analytics - Using Advanced Technologies and Methods to Monitor and Control Host Cell Proteins
- Plenary
Chairman
Workshop Overview
Host cell protein (HCP) impurities are the main process-related impurities in biological drugs and can pose a risk to patients and affect drug efficacy and stability. As a critical quality attribute, HCP levels must be carefully monitored and controlled to ensure product safety and efficacy.
HCP analytics have come a long way over the last 25 years. We have gone from a “black box” type approach that produced numbers that were semiquantitative at best to groundbreaking Mass Spectrometry techniques that can identify every host cell protein in a Drug Substance sample. HCP ELISA remains the workhorse for HCP analytics due to its utility, simplicity, robustness, and cost-effective nature. But we now have the tools to know exactly which HCP the assay can detect and which ones it will miss.
We will discuss how adoption of advanced technologies and methods for HCP analytics ensure that an HCP ELISA, whether it is a generic or a process-specific assay, is appropriate for use and allows data driven risk assessment to ensure drug product integrity and safety. Several case studies focusing on HCP antibody coverage assessment utilizing 2D PAGE- and MS-based methods will be presented. Additionally, data on LC-MS based HCP relative and absolute quantification will be presented.
Presenter
John LOCKLEAR
Associate Director - Assay Development and Technical Support
Cygnus Technologies
Workshop n°1 - Part II
Wednesday, 23 September 2026
11h10
Analytics for Other Process-related Impurities in Biologics: Protein A, Protein L, Host Cell DNA
- Plenary
Chairman
Workshop Overview
An overview of other host cell and process-related impurities, such as Protein A and Protein L Ligand Leachates, Host Cell DNA and requirements for impurity testing. Data and case studies utilizing Cygnus Technologies novel solutions for the reproducible detection and quantification of these impurities will be presented.
Presenter
John LOCKLEAR
Associate Director - Assay Development and Technical Support
Cygnus Technologies
Workshop n°2
Tuesday, 22 September 2026
11h10
Accelerated Regulatory Pathways to Saudi Arabia: New SFDA Programs by Development Stage
- Plenary
Chairman
Summary
Most companies file in Saudi Arabia only after FDA or EMA approval. In 2026, that sequence became costly. The SFDA now operates a set of designations and accelerator programs; several of them are for investigational medicines. This workshop maps each program to the development stage where it applies. Participants leave with a clear view of their options when approaching Saudi Arabia. It is the country with the highest rare disease prevalence in the Middle East and Africa, where around 8% of births are affected by a genetic condition.
Presenter
Mohammed JOBRAN
Regulatory Affairs Consultant & Founder
PharmaKnowl Consulting, KSA
Workshop n°3
Tuesday, 22 September 2026
11h10
Optimising Biologic Drug Products: Connecting Formulation Science, Process Development and Advanced Analytics
- Plenary
Chairman
Summary
The development of robust biologic drug products requires analytical strategies that provide insight from molecular structure to particle formation. In this workshop, Jean-François Boé, PhD (Senior Director, Drug Product Development, Catalent) and Waters experts will demonstrate how complementary analytical technologies, including liquid chromatography (LC), mass spectrometry (MS), multi-angle and dynamic light scattering (MALS and DLS), and Aura™ backgrounded membrane imaging, can be applied throughout formulation and process development.
Using real-world examples, attendees will learn how these orthogonal techniques can be used to characterise molecular variants, monitor aggregation and particle formation, assess formulation stability, and evaluate the impact of process changes on product quality. Join us to discover how integrated analytical workflows can accelerate development, strengthen process understanding, and support the creation of stable, manufacturable biologic drug products.
Speakers
Ben WILKES
Principal Biologics Market Development Manager
Waters Corporation, UK
Jean-François BOE
Senior Director, Drug Product Development
Catalent Biologics
Nicolas MIGNARD
Principal System Sales Account Manager, Biologics Business
Waters Corporation, France
Workshop n°4
Tuesday, 22 September 2026 and Wednesday, 23 September 2026
General title
11h10
Collaborative 3D Serious Game: Investigate three real deviation cases using data-driven analysis
- Plenary
Workshop Overview
Presenters
Cynthia HITTI
Digital Learning Sales Specialist
Immerscio.bio, France
Marc REIS
Customer Digital Solutions Specialist
Immerscio.bio, France
Farah DRISSI
Digital Learning Sales Specialist
Immerscio.bio, France
Workshop n°5
Tuesday, 22 September 2026
11h10
Decontamination in Bioproduction: Can Performance, Agility and Rapid Qualification Be Combined?
- Plenary
Chairman
Abstract
Bioproduction is becoming increasingly flexible and complex. Decontamination strategies must evolve accordingly: how can decontamination be made more flexible and easier to implement, while strengthening the level of scientific evidence?
Speaker